{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:31:44Z","timestamp":1790271104293,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":646,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1093\/annonc\/mdy015","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T20:10:28Z","timestamp":1516047028000},"page":"1010-1015","source":"Crossref","is-referenced-by-count":26,"title":["EVITA\u2014a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity"],"prefix":"10.1016","volume":"29","author":[{"given":"R.-D.","family":"Hofheinz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Lorenzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Trojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ocvirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.J.","family":"Ettrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-E.","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Homann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-P.","family":"Feustel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schatz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kripp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tetyusheva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Heeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vlassak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Merx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 5","key":"10.1093\/annonc\/mdy015_bb0010","first-page":"4","article-title":"Clinical presentation and pathophysiology of EGFRI dermatologic toxicities","volume":"21","author":"Mitchell","year":"2007","journal-title":"Oncology (Williston Park)"},{"key":"10.1093\/annonc\/mdy015_bb0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.critrevonc.2017.03.032","article-title":"Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors","volume":"114","author":"Hofheinz","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"issue":"8","key":"10.1093\/annonc\/mdy015_bb0020","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","article-title":"Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a preemptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer","volume":"28","author":"Lacouture","year":"2010","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1093\/annonc\/mdy015_bb0025","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1634\/theoncologist.2016-0051","article-title":"Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors","volume":"21","author":"Hofheinz","year":"2016","journal-title":"Oncologist"},{"issue":"4","key":"10.1093\/annonc\/mdy015_bb0030","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/cncr.23621","article-title":"Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes. Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB)","volume":"113","author":"Jatoi","year":"2008","journal-title":"Cancer"},{"issue":"10","key":"10.1093\/annonc\/mdy015_bb0035","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00520-010-0988-5","article-title":"Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB)","volume":"19","author":"Jatoi","year":"2011","journal-title":"Support Care Cancer"},{"key":"10.1093\/annonc\/mdy015_bb0040","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","article-title":"Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption","volume":"25","author":"Scope","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1093\/annonc\/mdy015_bb0045","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jaad.2016.01.019","article-title":"Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: a randomized, open-label trial","volume":"74","author":"Deplanque","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1093\/annonc\/mdy015_bb0050","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1200\/JCO.2015.62.3918","article-title":"Pan Canadian rash trial: a randomized phase III trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer","volume":"34","author":"Melosky","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1093\/annonc\/mdy015_bb0055","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.lungcan.2015.03.019","article-title":"Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients","volume":"88","author":"Arrieta","year":"2015","journal-title":"Lung Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdy015_bb0060","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdw227","article-title":"A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer","volume":"27","author":"Lacouture","year":"2016","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1093\/annonc\/mdy015_bb0065","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2217\/fon.14.251","article-title":"Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: hGCSG1001 study; J-STEPP","volume":"11","author":"Kobayashi","year":"2015","journal-title":"Future Oncol"},{"key":"10.1093\/annonc\/mdy015_bb0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.2478\/raon-2013-0014","article-title":"A review of the treatment options for skin rash induced by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis","volume":"47","author":"Ocvirk","year":"2013","journal-title":"Radiol Oncol"},{"key":"10.1093\/annonc\/mdy015_bb0075","unstructured":"http:\/\/lpi.oregonstate.edu\/mic\/vitamins\/vitamin-K (23 January 2018, date last accessed)."},{"issue":"7","key":"10.1093\/annonc\/mdy015_bb0080","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.febslet.2006.02.048","article-title":"Activation of ErbB2 by 2-methyl-1, 4-naphthoquinone (menadione) in human keratinocytes: role of EGFR and protein tyrosine phosphatases","volume":"580","author":"Beier","year":"2006","journal-title":"FEBS Lett"},{"issue":"21","key":"10.1093\/annonc\/mdy015_bb0085","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1158\/1078-0432.CCR-11-0545","article-title":"The phosphatase inhibitor menadione (vitamin K3) protects cells from EGFR inhibition by erlotinib and cetuximab","volume":"17","author":"Perez-Soler","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1093\/annonc\/mdy015_bb0090","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1468-3083.2011.04324.x","article-title":"Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis","volume":"27","author":"Tomkov\u00e1","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"10.1093\/annonc\/mdy015_bb0095","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clcc.2013.10.001","article-title":"Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer","volume":"13","author":"Pinta","year":"2014","journal-title":"Clin Colorectal Cancer"},{"issue":"Suppl 1","key":"10.1093\/annonc\/mdy015_bb0100","first-page":"S106","article-title":"The prophylactic use of K1 cream for reduction of skin toxicity during the cetuximab treatment","volume":"20","author":"Ocvirk","year":"2012","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1093\/annonc\/mdy015_bb0105","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s00520-009-0744-x","article-title":"A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group","volume":"18","author":"Lacouture","year":"2010","journal-title":"Support Care Cancer"},{"issue":"9","key":"10.1093\/annonc\/mdy015_bb0110","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1600-0625.2008.00715.x","article-title":"A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition","volume":"17","author":"Wollenberg","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1093\/annonc\/mdy015_bb0115","unstructured":"https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/Archive\/CTCAE_4.02_2009-09-15_QuickReference:8.5x11.pdf (23 January 2018, date last accessed)."},{"issue":"3","key":"10.1093\/annonc\/mdy015_bb0120","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI) \u2013 a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1093\/annonc\/mdy015_bb0125","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00520-012-1623-4","article-title":"The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18)","volume":"21","author":"Wagner","year":"2013","journal-title":"Support Care Cancer"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419454653?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419454653?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/29\/4\/1010\/24702590\/mdy015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T09:40:39Z","timestamp":1624700439000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419454653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0923753419454653"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdy015","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]}}}